Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)Razelle Kurzrock, Rashmi Chugh, Adrienne I. Victor et al.|Journal for ImmunoTherapy of Cancer|2021Cited by 159